• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[依达赛珠单抗成功治疗急性肾损伤患者的严重达比加群中毒]

[Successful treatment of severe dabigatran intoxication with idarucizumab in a patient with acute kidney injury].

作者信息

Poulsen Christina Gjerlev, Bestle Morten, Boesby Lene

出版信息

Ugeskr Laeger. 2017 Feb 13;179(7).

PMID:28397672
Abstract

In the course of an uncomplicated sigmoidostomy a 63-year-old male who had severe comorbidity developed a critical bleeding due to dabigatran intoxication induced by acute kidney injury. Massive blood transfusions, tranexamic acid, Octaplex and haemodialysis were not effective. Administration of idarucizumab induced immediate clinical and paraclinical improvement. Dabigatran should be carefully administrated in patients who have any degree of renal insufficiency. Idarucizumab may be effective in severe bleeding caused by dabigatran.

摘要

在一次简单的乙状结肠造口术中,一名患有严重合并症的63岁男性因急性肾损伤导致达比加群中毒而发生严重出血。大量输血、氨甲环酸、凝血因子复合物和血液透析均无效。给予依达赛珠单抗后临床和辅助检查结果立即改善。对于有任何程度肾功能不全的患者,应谨慎使用达比加群。依达赛珠单抗可能对达比加群引起的严重出血有效。

相似文献

1
[Successful treatment of severe dabigatran intoxication with idarucizumab in a patient with acute kidney injury].[依达赛珠单抗成功治疗急性肾损伤患者的严重达比加群中毒]
Ugeskr Laeger. 2017 Feb 13;179(7).
2
Idarucizumab for dabigatran overdose.依达赛珠单抗用于达比加群过量。
Clin Toxicol (Phila). 2016 Sep;54(8):644-6. doi: 10.1080/15563650.2016.1187737. Epub 2016 May 25.
3
idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.依达赛珠单抗(Praxbind®)。不要过度依赖这种达比加群解毒剂。
Prescrire Int. 2016 Nov;25(176):260-263.
4
[TEG-guided treatment of a dabigatran overdose in a patient with acute kidney failure].
Anaesthesist. 2020 Aug;69(8):573-578. doi: 10.1007/s00101-020-00801-x. Epub 2020 Jun 20.
5
Idarucizumab: The Antidote for Reversal of Dabigatran.艾达司珠单抗:达比加群逆转的解毒剂。
Circulation. 2015 Dec 22;132(25):2412-22. doi: 10.1161/CIRCULATIONAHA.115.019628.
6
Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.达比加群逆转剂依达鲁珠单抗:单中心真实世界经验。
Am J Cardiovasc Drugs. 2019 Feb;19(1):59-64. doi: 10.1007/s40256-018-0300-5.
7
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.依达赛珠单抗,一种达比加群的特异性逆转剂:作用机制、药代动力学和药效学以及1期受试者的安全性和有效性。
Am J Med. 2016 Nov;129(11S):S64-S72. doi: 10.1016/j.amjmed.2016.06.007. Epub 2016 Aug 26.
8
Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.使用依达赛珠单抗逆转急性肾损伤出血患者的达比加群效应。
Thromb Haemost. 2017 Jan 5;117(1):196-197. doi: 10.1160/TH16-06-0445. Epub 2016 Oct 13.
9
Management of dabigatran after overdosage: two case reports and suggestions for monitoring.
Blood Coagul Fibrinolysis. 2018 Nov;29(7):653-655. doi: 10.1097/MBC.0000000000000763.
10
Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.作为达比加群的副作用,出现胆汁淤积性肝损伤,以及在出血和脓毒症时应用idarucizumab逆转达比加群抗凝作用后,检测凝血试验的应用。
Scand J Clin Lab Invest. 2018 Feb-Apr;78(1-2):1-5. doi: 10.1080/00365513.2017.1402127. Epub 2017 Nov 17.